SOURCE: Research and Markets

Research and Markets

February 16, 2016 10:51 ET

Global Immune Checkpoint Inhibitors Market Report -- Analysis, Technologies & Forecast 2015-2025 -- Key Vendors: Abbott, CureTech & Evogene

DUBLIN, IRELAND--(Marketwired - February 16, 2016) - Research and Markets has announced the addition of the "Immune Checkpoint Inhibitors Market (2nd edition), 2015-2025" report to their offering.

The 'Immune Checkpoint Inhibitors Market (2nd edition), 2015-2025' report provides a comprehensive analysis of the current market landscape and the future outlook of the growing pipeline of Immune Checkpoint Inhibitors. The immuno-oncology market encompasses a myriad of immune checkpoint targeting drugs which can be potentially exploited for a broad range of cancer indications. Specifically, CTLA-4 inhibitors were the pioneers in this segment. Yervoy, the flagship molecule from BMS, was the only immunotherapeutic commercially available until other classes recently stepped in. The recent approval of anti PD-1 drugs and emergence of anti PD-L1 drugs has provided a significant boost to the market.

In addition, there are several novel checkpoint inhibitors (e.g. IDO, LAG-3, CD70, OX40, CD40, GITR, TIM-3, CD137/4-1BB, KIR, TDO, VISTA, CS1, NKG2A, GARP, ICOS) which have recently gained ground and are expected to retain attention in the future.

One of the key objectives of the study is to review the prospects laid by the robust, opportunistic and broad pipelines of the pharmaceutical firms. With three marketed drugs (Yervoy, Keytruda and Opdivo), the market is treading its way towards fulfilling the huge untapped promise. Amongst other elements, the report elaborates upon the following key areas:

  • The current state of the market with respect to key players, developmental stage of pipeline products (both clinical / pre-clinical) and indications targeted
  • Recent partnerships which have taken place over the last five years including product co-development, licensing and clinical trial collaborations
  • Combination therapies where Immune Checkpoint Inhibitors are being evaluated in combination with other anti-cancer agents/therapies
  • Various investments and grants received by the companies focused in this area
  • Competitive landscape and inherent threats to growth in the short and long term
  • Development and sales potential based on target consumer segments, likely adoption rate and expected pricing

Companies Mentioned Include:

  • Abbott
  • AbbVie
  • Adimab
  • Amgen
  • Amplimmune
  • AnaptysBio
  • Aravis Ventures
  • Curadev
  • CureTech
  • Curis
  • CX Venture Group
  • de Duve Institute
  • Dendreon
  • Eddingpharm
  • Eisai
  • Eli Lilly and Company
  • EMD Serono
  • Endocyte
  • ESCO Congress
  • Evogene
  • Facet Biotech
  • Flexus Bioscience
  • Janssen Biotech
  • Juno Therapeutics
  • KAHR Medical
  • KBC Securities
  • Lonza Biologics
  • Theravectys
  • Wyeth

For more information visit http://www.researchandmarkets.com/research/dl52fn/immune_checkpoint

About Research and Markets
Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Sector: Oncology

Image Available: http://www.marketwire.com/library/MwGo/2016/2/16/11G083015/Images/immune_checkpoint_inhibitors_market_2nd-016de3bbf56d8d9b8b4076119cfd4cf0.jpg

Contact Information

  • Research and Markets
    Laura Wood
    Senior Manager
    press@researchandmarkets.com

    For E.S.T Office Hours Call 1-917-300-0470
    For U.S./CAN Toll Free Call 1-800-526-8630
    For GMT Office Hours Call +353-1-416-8900

    U.S. Fax: 646-607-1907
    Fax (outside U.S.): +353-1-481-1716